Dr. Colowick is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
355 Santa Rita Avenue
Menlo Park, CA 94025Phone+1 650-330-1279
Education & Training
Stanford University School of MedicineClass of 1991
Publications & Presentations
PubMed
- 5 citationsA randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for maligna...John A Glaspy, Jaswant Sinh Jadeja, Glen Justice, Alex Fleishman, Gregory Rossi
Cancer. 2003-03-01 - 63 citationsA dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer.R E Smith, N S Tchekmedyian, D Chan, L A Meza, Donald W. Northfelt
British Journal of Cancer. 2003-06-16 - 379 citationsDouble-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving ChemotherapyJohan Vansteenkiste, Robert Pirker, Bartomeu Massuti, Fernando Barata, Albert Font
Journal of the National Cancer Institute. 2002-08-21
Press Mentions
Teon Therapeutics Names Serge Messerlian as CEOMarch 8th, 2022- Harpoon Therapeutics Appoints Experienced Biotech Leader Alan Colowick, M.D., to Board of DirectorsMarch 24th, 2021
XyloCor Therapeutics Raises $17 Million in Series A Financing to Advance Gene Therapy Portfolio in Cardiovascular DiseaseDecember 6th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
